Completed PHASE3 INTERVENTIONAL 1-arm NCT01467661

Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Sponsor: Shire

Conditions Essential Thrombocythemia (ET)

Interventions SPD422 (anagrelide hydrochloride)

Updated 9 times since 2017 Last updated: May 24, 2021 Started: Oct 27, 2010 Primary completion: May 1, 2015 Completion: May 1, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Essential Thrombocythemia (ET), this trial is completed. The trial is conducted by Shire and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

May 2019 — Jan 2021 [monthly]

Completed PHASE3
Jan 2019 — May 2019 [monthly]

Completed PHASE3
Jun 2018 — Jan 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akita, Japan , Chuo-ku Inohana 1-8-1, Japan , Higashigaoka 2-5-1, Japan , Honkomagome 3-18-22, Japan , Isehara-shi, Japan , Izunokuni-shi, Japan , Miyazaki, Japan , Niigata, Japan , Okayama, Japan , Osaka, Japan and 6 more locations